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Abstract 
To better understand how stigma resistance impacts functioning-related domains, we examined 
mean effect sizes between stigma resistance and: 1) symptoms (overall, positive, negative, and 
mood symptoms); 2) self-stigma; 3) self-efficacy; 4) quality of life; 5) recovery; 6) hope; and 7) 
insight, and 8) overall outcomes (the average effect size across the constructs examined in each 
study). The mean effect size between stigma resistance and overall outcomes was significant and 
positive (r = 0.46, p <0.001, k = 48). A large, negative effect size was found between stigma 
resistance and self-stigma (r = -0.57, p<.001, k = 40). Large, positive effect sizes were found 
with self-efficacy (r = 0.60, p < 0.001, k = 25), quality of life (r = 0.51, p < 0.001, k = 17), hope 
(r = 0.54, p <0.001, k = 8), and recovery (r = 0.60, p<0.001, k = 7). Stigma resistance had a 
significant medium and small relationship with insight and symptoms, respectively. Race 
significantly moderated overall outcomes, self-stigma, mood symptoms, functioning, and hope 
associations. Education significantly moderated symptoms, functioning, and mood symptoms 
associations, and age significantly moderated self-stigma and negative symptom associations. 
Stigma resistance may be a key requirement for recovery. Individual characteristics influence 
resisting stigma and future work should prioritize cultural factors surrounding stigma resistance.  
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1. Introduction 
Public stigma—negative attitudes, actions, or beliefs about mental illness (Link and Phelan, 
2001)—is prevalent (Vahabzadeh et al., 2011) and often leads to negative treatment of those with 
severe mental illness (e.g., discrimination; Corrigan et al., 2012; Stuart, 2004). Stigma also has 
the potential to affect how people view or treat themselves. Self-stigma involves moving beyond 
awareness of public stigma to agreeing with it and applying it to oneself (Corrigan and 
O'Shaughnessy, 2007; Watson et al., 2007). When public stigma is internalized, it can lead to 
decreased hope, quality of life, self-esteem, and greater symptom severity, including depression 
(Hasson-Ohayon et al., 2014; Lipsey and Wilson, 2001; Staring et al., 2013), as well as reduced 
help-seeking (Clement et al., 2015).  
Given the strong relationships between self-stigma and poorer recovery-related outcomes 
(Yanos et al., 2008), greater attention has turned to understanding the process (or processes) by 
which stigma is resisted (Boyd et al., 2004; Sibitz et al., 2011).  Past work has conceptualized 
stigma resistance as being unaffected by stigmatizing attitudes (Boyd et al., 2004; Ritsher et al., 
2003) as well as more actively challenging or deflecting encounters with stigma (Thoits, 2011). 
Theoretical work on stigma resistance suggests that resisting stigma may lead to individuals from 
stigmatized groups experiencing greater empowerment (Campbell and Deacon, 2006). 
Specifically, resisting stigma may involve rejecting a social identity that is tied to stigma as well 
as an increased sense of agency. Thoits (2011) further theorized that particular factors may be 
key to helping individuals resist stigma more effectively, such as having greater resources, 
experincing positive outcomes from resisting stigma previously, posessing multuiple role- 
identities outside of being a person with a mental illness, or experiences with peers who are 
resisting stigma. Although originally examined as part of larger self-stigma measures (King et 
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al., 2007; Rister et al., 2003), stigma resitance has since been discussed theoretically (Thotis, 
2011) and psychometrically (Sibitz et al., 2011) as distinct from self-stigma. While recent work 
has emphasized the need to further study stigma resitance, it remains relatively under-studied, 
particularly in comparison to self-stigma (Nabors et al., 2014; Sititz et al., 2011; Thoits, 2011). 
One factor that may contribute to the lack of attention on stigma restiance in the literature relates 
to measurement issues that accompany existing measures of this construct.  
The most commonly used measure is the “Stigma Resistance” subscale of the 
Internalized Stigma of Mental Illness Scale (ISMIS; Ritsher et al., 2003). This subscale is 
comprised of 5 reverse-scored items that reflect a positive illness identity, such as “I can have a 
good, fulfilling life, despite my mental illness” and “Living with mental illness has made me a 
tough survivor.” Although assessed as part of internalized stigma, a recent factor analysis 
revealed the stigma resistance items form a unique factor from the rest of the ISMIS items (Sibitz 
et al., 2011). In addition to the ISMIS, a less widely used assessment that taps a construct highly 
related to stigma resistance is the “Positive Aspects” subscale of the Stigma Scale (King et al., 
2007). This subscale also consists of 5 items that assess a positive illness identity (e.g., “Having 
had a mental health problem has made me a more understanding person,” or “Having had mental 
health problems has made me a stronger person”).  
 However, issues with both scales have led to inconsistent usage of both instruments. 
First, although the overall ISMIS has shown good reliability (Boyd et al., 2014), the Stigma 
Resistance subscale scores have variable reliability (Ritsher et al., 2003). As a result, some 
research on self-stigma using the ISMIS calculates a self-stigma score that excludes Stigma 
Resistance subscale or examines this sub-scale separately (Lysaker et al., 2012; Mashiach-
Eizenberg et al., 2013; Park et al., 2013). More recent studies have examined the item loadings 
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of the ISMIS and conclude that the Stigma Resistance items comprise a distinct factor from the 
remainder of the ISMIS, and recent studies have also demonstrated adequate reliability of this 
sub-scale in samples with schizophrenia spectrum disorders (Campellone et al., 2014; Nabors et 
al., 2014). Next, while the Positive Aspects subscale scores of the Stigma Scale have shown 
adequate reliability (King et al., 2007), it remains infrequently used. This may be, in part, due to 
the less frequent use of the Stigma Scale. Despite the limitations of existing measures, both 
measures have demonstrated good construct validity in the validation work and subsequent 
studies. For example, in the validation study for the ISMIS, the Stigma Resistance sub-scale was 
positively associated with self-esteem and recovery and negatively associated with self-stigma 
and depressive symptoms; similarly, in the Stigma Scale validation, the Positive Aspects sub-
scale was negatively related to self-stigma and positively related to self-esteem (Stuart, 2004; 
King et al., 2007).  
 Understanding the relationship between stigma resistance and outcomes across existing 
literature is important in order to further shed light on the process of stigma resistance, the link 
between stigma resistance and some of the negative outcomes that frequently accompany self-
stigma, and how interventions might address stigma resistance. Before work continues in this 
important area, a synthesis of existing literature is needed in order to establish existing 
relationships between resisting stigma and outcomes, as well as identify the impact of 
measurement issues. The present study is a meta-analysis examining the relationship between 
stigma resistance and symptoms and functioning-related outcome variables. Employing meta-
analytic methods, furthermore, allows us to apply artifact corrections to the statistical analyses in 
order to determine the mean effect size of relationships with and without the influence of 
measurement error. Therefore, this study will also examine the degree to which measurement 
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error is impacting current measurements of stigma resistance’s relationship with outcomes. To 
our knowledge, no systematic review or meta-analysis of mental health stigma resistance has 
been conducted, and only one theoretical paper has discussed the construct in the context of 
mental health (Thoits, 2011). Aims and hypotheses of the current study include: 
(1) Assessing the strength and direction of the relationship between stigma resistance and 
overall outcomes, as well as the relationship between stigma resistance and symptoms 
(overall, positive, negative, and mood), self-efficacy, quality of life, recovery, hope, and 
insight. We hypothesize that stigma resistance will have a positive relationship with 
quality of life, hope, recovery, insight, and self-efficacy; stigma resistance will be 
negatively related to symptoms and self-stigma. 
(2) Examining moderators of these relationships, including age, gender, race, education 
level, and diagnosis of sample participants.  We hypothesize that relationships between 
stigma resistance and outcomes will be stronger with increasing age, given that increased 
age has been associated with lower self-stigma (Werner et al., 2008). Because stigma 
may be greater toward some clinical diagnoses and this treatment may worsen one’s 
experience of mental illness (Corrigan, 2007), we hypothesize that having a 
schizophrenia-spectrum diagnosis will be associated with a weaker relationship between 
stigma resistance and positive outcomes.  Other moderator analyses were exploratory. 
(3) Examine the degree to which psychometric properties of current measures of stigma 
resistance affect the ability to detect potential relationships. We estimate the level of 
impact of poor reliability on attenuated correlations by calculating standard effect sizes as 
well as effect sizes adjusted for internal consistency (Card, 2012).  
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2. Method 
2.1 Literature Search 
 We used PRISMA guidelines for conducting and reporting our meta-analysis (Moher et 
al., 2009). Studies were identified through conducting searches in the electronic databases 
PsycINFO, PsycARTICLES, Pubmed, Medline, Web of Science, and Embase. Key-words 
searched included: Internalized stigma of mental illness, stigma resist*, self stigma and mental 
health, self stigma scale. Studies published through May 15th 2015 were eligible. If studies 
reported self-stigma using the ISMIS, but did not report the stigma resistance subscale data in 
their published work, authors were contacted. We conducted forward searches of reference lists 
and citations of key articles. See Figure 1 for the Study Retrieval Flowchart.  
2.2 Study Selection: Inclusion and Exclusion Criteria 
To be included in analyses, studies needed to (1) report bivariate relationships between 
symptoms or a functioning-related outcome variable and either the Stigma Resistance subscale of 
the ISMIS or the Positive Aspects subscale of the Stigma Scale, (2) assess stigma in an adult 
mental health sample (those with a diagnosis and/or in a mental health treatment setting), and (3) 
be available in English. Studies were excluded if sufficient information was not available after 
contacting the author or when a study’s sample overlapped with that of another study. If studies 
involved an intervention-design, only baseline relationships were examined. We also included 
dissertation/thesis reports.  
 A total of 791 unique, full-text records were screened for eligibility. The most common 
reasons for excluding articles were if the ISMIS/Stigma Scale was not used or participants were 
a non-mental health sample.  Initially, only ten studies included sufficient information for 
analyses in the published record. For studies in which the ISMIS was used, but stigma resistance 
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was not included in the publication, we contacted authors (n = 95), with multiple requests for 
authors who did not respond. Of these requests, author responses provided data for 38 additional 
records. In order to avoid inflating the overall mean effect sizes (Card, 2012), when multiple 
papers were taken from the same sample of participants, effect sizes were only used from one 
study (See Figure 1 for full study retrieval details).  
2.3 Coding 
 Studies were coded according to a modified codebook (Lipsey and Wilson, 2001) and 
described below. A select number of studies were randomly selected for double coding (k = 19; 
40.4%) whereby two researchers independently coded study information and consensus was 
researched to ensure accuracy of data coded.  
2.3.1 Basic study information. We coded publication year and average sample size. We 
coded the measure of stigma resistance used; however, because so few studies used the Stigma 
Scale (versus the ISMIS), categorical moderation analyses were not performed with subgroups of 
less than 4 (Lipsey and Wilson, 2001). Similarly, the language in which measures were 
administered was also coded but there was insufficient variability to assess for moderation. 
2.3.2 Sample characteristics. Sample characteristics included demographic information 
coded as continuous moderators: mean sample age, gender (percent female), race (percent 
White), mean level of education, and diagnosis (percent with a schizophrenia-spectrum 
diagnosis).  
2.3.3 Effect size. For each study, the effect size between stigma resistance and symptoms 
and/or functioning-related outcome variables was coded. Similar constructs were then grouped to 
calculate mean effect sizes. Ten main symptom and functioning-related outcomes were reported 
across the studies (i.e., self-stigma, overall symptoms, positive symptoms, negative symptoms, 
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mood symptoms, self-efficacy, quality of life, recovery, hope, and insight), so results represent 
the mean relationship between stigma resistance and each of these ten categories. When an 
outcome construct was measured in multiple ways or contained sub-groupings (e.g., positive, 
negative, and mood symptoms), a set of sub-codes were applied so further analyses could be 
conducted at the sub-group level. An overall outcome effect size was also computed for each 
study by calculating an average of the effect sizes of the reported relationships with stigma 
resistance. This involved reverse-scoring effect sizes that reported negative relationships with 
stigma resistance (e.g., symptoms or self-stigma). Each study provided one overall effect size 
and potentially one effect size per construct. Coding was entered into SPSS version 21.0.  
2.4 Meta-Analytic Method 
 Effect sizes were calculated using a random effects model because it assumes that effect 
sizes are similar (but not identical) across studies due to effects of within-study and between-
study variability (Lipsey and Wilson, 2001). When a study reported multiple measures of the 
same construct (or constructs considered similar and grouped for the purposes of this meta-
analyses), an average of these effect sizes was used and weighted by sample size in order to 
maintain statistical independence (Card, 2012). This weighted average was used to calculate the 
“overall outcomes” effect size. When samples overlapped (different reports of sample that shared 
the same participants), the larger sample size was used. 
Before mean effect sizes were conducted, individual study level effect sizes were 
transformed using Fisher’s r-to-Z-transformation to adjust for the non-normal distribution of 
Pearson’s r, and then the inverse variance was applied to weight by sample size. To calculate the 
mean effect sizes, a macro (“MeanES”) was used in SPSS version 21.0 (Wilson, 2010). The 
strength of the mean effect sizes were discussed in light of Cohen’s (1992) recommendations 
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(small = .10-.29, medium = .30-.49, large = .50 and above; Cohen, 1992). Orin’s Fail-safe N’s 
were also conducted to examine the strength of effect sizes and to determine the number of null 
findings necessary to bring each mean effect size to below a meaningful level (ES <.15; Lipsey 
and Wilson, 2001).  
 To address aim two and test for potential moderation, the heterogeneity across studies 
was examined using the Q-statistic generated by Wilson’s (2010) macro. Significant results 
(p<.10) suggest that effect sizes may be drawn from more than one population (Sagie, 1993). The 
Q-statistic was then used to calculate the I2 index. While a significant Q-statistic informs whether 
moderation may be present, the I2 index informs the extent of the heterogeneity (Higgins and 
Thompson, 2002; Huedo-Medina et al., 2006). I2 values below 25% reflect low heterogeneity, 
25%-50% medium heterogeneity, 50%-75% high heterogeneity, and above 75% extreme 
heterogeneity (Fazel et al., 2009).  I2 values greater than or equal to 25% were examined for the 
presence of moderators, as this suggests between study variability in effect sizes was greater than 
expected by chance and this threshold has been used in other meta-analyses (Huedo-Medina et 
al., 2006).  
Meta-regressions were run to test moderator variables using a macro provided by Wilson 
(2010), “MetaReg,” which runs a weighted generalized least squares regression (Wilson, 2010). 
The following continuous moderators were examined: mean age, mean education, percent 
female, percent White, and percent of the sample with a schizophrenia-spectrum diagnosis. 
Regressions were run using the mixed effects model, allowing results to be estimated using 
errors associated with sampling differences or moderator variables, as well as random, 
unidentified factors such as unidentified moderators (Lipsey and Wilson, 2001). Because meta-
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regressions use list-wise deletion, each moderator was examined independently in order to 
maximize the number of studies included in the analysis.  
To address aim three, we conducted separate analyses using corrected and uncorrected 
data.  An artifact correction was applied using the formula provided by Card (2010) in order to 
correct for the poor reliability of the stigma resistance scales and under-weight studies with 
lower scale reliability. This technique was applied in order to generate an estimate of the effect 
sizes likely if psychometric reliability were not limiting the detection of effect size strength 
(Card, 2010). Artifact corrections were applied only to the stigma resistance scales in order to 
isolate the effect of the psychometric properties specific to these scales. Analyses presented as 
the primary results use corrected effect sizes but uncorrected effect sizes were also analyzed and 
are discussed in light of broader psychometric issues.  
3. Results 
 
3.1 Sample 
Forty eight (45 journal articles and three published dissertation/theses) were included in 
the meta-analyses, from which 165 unique effect sizes were coded. The mean publication year 
was 2012 (SD = 2.2 years; range = 2003-2015). The mean sample size was 170.6 (SD = 265.9; 
range = 21-1811). The mean sample age was 43.0 (SD = 6.5; range = 24.6-59.6) and the mean 
level of education was 12.5 years (SD = 1.5 years; range = 9.0-14.7). On average, samples were 
comprised of 46.0% women and 47.6% White participants. On average, study samples were 
comprised of 65.2% participants with schizophrenia-spectrum disorders; moreover, 20 samples 
were entirely comprised (100%) of participants with schizophrenia-spectrum disorder diagnoses. 
Three studies used the Stigma Scale and 45 used the ISMIS. The mean stigma resistance score 
on the ISMIS was 2.7 (out of 5-point mean score; SD = 2.1; range = 1.1-2.9) and the mean 
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positive aspects score on the Stigma Scale was 10.4 (out of a 40-point total score; SD = 4.8; 
range = 8.8-11.9). The mean internal reliability for the stigma resistance scales included in the 
overall analysis was .56 (SD=.13).  
3.2 Mean Effect Sizes 
The relationship between stigma resistance and overall outcomes was a significant, 
medium effect (r =.46; K =48). The mean effect sizes for the relationship between stigma 
resistance and each outcome construct was also statistically significant. The strongest 
associations were a significant, large negative mean effect size with self-stigma (r = -0.57; K = 
40) and significant, large positive mean effect sizes with self-efficacy (r = .60; K=25), recovery 
(r =.60; K=7), hope (r = .54; K=8), and quality of life (r = .51; K=17). Resisting stigma also had 
a significant, medium effect size with insight (r = .38; K = 4) and significant, small associations 
with overall symptoms (r =-.28; K=20) and each symptom sub-domain. See Table 2 for 
additional statistics on the mean effect size associations.  
Orwin’s Fail-safe N was also calculated to reveal the number of omitted studies with zero 
correlations needed to drive each mean association to an inconsequential level (e.g., <.15; Moher 
et al., 2009). Orwin’s N values showed most mean effect associations to be fairly robust against 
potential file-drawer limitations. For example, approximately 85 studies with insignificant mean 
effects would be needed to drive the mean association between stigma resistance and overall 
outcomes to an inconsequential level, 65 for the self-efficacy association, 35 studies would be 
needed for the self-stigma association, and 21 for the recovery association. However, only 5 
studies with insignificant finding would drive the mean effect size for the association between 
stigma resistance and insight to an inconsequential level, suggesting less confidence in the 
insight finding. 
  13 
 
3.3 Moderator Analyses 
Heterogeneity analyses were significant for the stigma resistance–overall outcomes 
association, as well as for 9 of the additional mean effect sizes. This suggests that these 
associations were being impacted by between-study variability greater than would be expected 
by chance. The only mean effect size not impacted by high between-study variability was the 
association between stigma resistance and positive symptoms (Q =3.6) The remaining mean 
effect sizes not only had significant Q values, but also had large I2 values, strongly suggesting the 
presence of moderator variables. Moderation analyses are presented in Table 3. Contrary to our 
hypotheses, participant mean age only significantly moderated the relationship between stigma 
resistance and self-stigma and negative symptoms. Education significantly moderated the 
relationship between stigma resistance and self-stigma, overall symptoms, mood symptoms, and 
quality of life. The percent of the sample with schizophrenia-spectrum diagnoses and participant 
sex were not significant moderator for any associations examined. Race significantly moderated 
the relationship between stigma resistance and overall outcomes, self-stigma, mood symptoms, 
quality of life, and hope.     
3.4 Psychometric Reliability of Stigma Resistance Measures  
Finally, we examined mean effect sizes both adjusting for and not adjusting for internal 
consistency of the stigma resistance measure. When uncorrected effect sizes were computed, all 
of the 11 outcome constructs were lower than the non-corrected effect sizes but remained 
significant (See Table 2).  
4. Discussion 
In light of the growing interest in stigma resistance, this meta-analysis offers an important 
contribution to this expanding area of work by synthesizing relationships between stigma 
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resistance and a variety of psychosocial and psychiatric outcomes, illuminating important 
relationships. Indeed, our findings point to stigma resistance potentially having a central role in 
recovery. Stigma resistance was significantly related to each outcome domain in the 
hypothesized direction, with greater stigma resistance being related to greater overall outcomes, 
self-efficacy, quality of life, recovery, hope, insight and lower levels of symptoms and self-
stigma. This meta-analysis also offers a unique contribution by gathering a substantial amount of 
unpublished data, as only 10 published studies originally included relevant data.  With the 
generous assistance of many authors, the present study synthesizes data for 48 reports on stigma 
resistance and outcomes, reflecting data for 8,187 individuals.  
Findings of large, significant effect sizes between stigma resistance and recovery, self-
efficacy, hope, and quality of life suggest these domains may be particularly relevant to stigma 
resistance. Theoretical work by Thoits (2011) posits that stigma resistance involves challenging 
stereotypes and the application of stereotypes to oneself and that resisting stigma is facilitated by 
a sense of identity that extends beyond one’s mental illness. An important component of stigma 
resistance reflected in the items of both stigma resistance measures we included in these analyses 
(i.e., the ISMIS and SS) is that of having a positive illness identity. This conceptualization is 
supported by the strength and direction of the mean effect sizes observed in our findings. That is, 
as one had greater stigma resistance, one had increased self-efficacy, hope, and recovery scores.  
The present findings also build on those reported in Livingston and Boyd’s (2010) meta-
analysis of correlates of self-stigma that found greater self-stigma being associated with 
decreased self-esteem, empowerment, self-efficacy, quality of life, hope, and social support. At 
the time of Livingston and Boyd’s self-stigma meta-analysis, only ten reports were available 
using the ISMIS. Our study was able to contribute to the synthesis of this literature by comparing 
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associations between self-stigma and outcomes with the present findings on stigma resistance 
and outcomes. Consistent with our hypothesis, the present findings revealed a large, negative 
relationship between stigma resistance and self-stigma. However, of note, the magnitude of this 
relationship was not so large as to suggest these are two sides of the same construct. That is, 
although strongly related, we believe several associations in the present findings support stigma 
resistance as distinct from self-stigma.  For instance, building on Sibitz et al (2011)’s report that 
the stigma resistance subscale comprises a distinct factor from the remainder of the ISMIS, we 
also found that stigma resistance was significantly related to negative symptoms, a relationship 
not observed in relation to self-stigma (Lipsey and Wilson, 2001; Nabors et al., 2014). 
Particularly given the increasing popularity of the ISMIS tool, more work is needed to determine 
distinctions between the relationship of self-stigma and stigma resistance with outcomes.   
These results also shed light on variables that moderate associations between stigma 
resistance and specific outcomes. First, participant race significantly moderated the relationship 
between stigma resistance and overall symptoms as well as mood symptoms so that having a 
sample with a greater number of White participants meant stigma resistance had a stronger 
positive relationship with symptoms. While these findings need replication and further work, 
they may suggest potential areas for important future investigation. For example, past work has 
discussed the construct of “double stigma,” (Gary, 2005), whereby individuals from 
disadvantaged groups face compounding barriers and stigmas. Furthermore, groups who 
experience social devaluation from multiple sources might particularly benefit from interventions 
that provide external support in the stigma resistance process (Gary, 2005). Further work should 
investigate whether and how race and mental illness stigmas may interact and the impact this 
may have on one’s experiences resisting stigma. Participant age was also a significant moderator 
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for associations between stigma resistance and self-stigma and negative symptoms. This may 
suggest that an important area for future investigation will be understanding whether distinct 
factors impact resisting stigma early versus late in the course of one’s illness. For example, 
social support has been linked to reduced self-stigma among those with early phase psychosis 
(Mueller et al., 2006) and future work could consider how to most effectively assist individuals 
resist stigma early in their course of illness. It may also be that age is an important variable 
because it is related to the development of one’s self-concept (Piers & Harris, 1964; Shavelson, 
Hubner, & Stanton, 1976). Indeed, possessing a richer sense of identity and ability to articulate 
one’s personal narrative have been linked with greater recovery (Firmin et al., 2015; Lysaker, 
Roe, & Yanos, 2007; Yanos, Roe, Markus, & Lysaker, 2008). Taken together, future work 
should pursue how stigma may shape one’s self-concept and how interventions may help 
promote one’s self-concept in the face of stigma, particularly during critical periods in one’s 
developmental identity formation.   
Some moderation findings were contrary to our hypotheses, such as the lack of 
moderation related to samples with higher schizophrenia-spectrum disorders. Initially, we drew 
this hypothesis from literature suggesting individuals with schizophrenia-spectrum disorders may 
face greater public stigma, which may then worsen one’s experience of mental health symptoms 
(Corrigan, 2007). It may be that the lack of significant moderation in our study suggests that 
stigma resistance is something individuals with even the most severe and stigmatized diagnoses 
can engage in effectively. However, it is possible that the lack of moderation in our findings 
stems from methodological issues, such as variability across studies in how diagnoses were 
assessed and assigned (e.g., chart review, self-report, researcher rated).  
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In order to examine measurement issues, this study also analyzed corrected and 
uncorrected effect sizes and found that both sets of analysis revealed significant relationships in 
the hypothesized directions. Given that mean effect sizes were stronger when studies with poor 
reliability were under-weighted, these findings point to ample room for the improvement of 
existing measurement tools. At the same time, the significant effect sizes observed using 
uncorrected data—largely gathered through contacting authors for unpublished analyses—
suggests relationship between stigma resistance and symptoms and outcomes have largely been 
under-studied.  
This study has several limitations. First, all studies were cross-sectional and correlational. 
As Livingston and Boyd (2010) noted, the lack of longitudinal work in this area significantly 
limits clinical implications and interpretations regarding causality and directionality of 
associations found. However, given the state of the literature, the current synthesis is an 
important step that can inform the direction of longitudinal investigations. Another issue, 
common in many meta-analyses and known as the “file drawer problem,” is publication bias 
toward significant findings (Card, 2012). Additionally, and particularly salient in this study, 
stigma resistance associations were frequently excluded from publications. Yet, we were able to 
contact many authors with existing, unpublished data and, for data we could include, we found 
significant relationships. In addition, Orwin’s fail-safe N analyses indicated that a relatively large 
number of studies with non-significant findings would be needed to drop the mean effect sizes 
for most of the association included in this study to an inconsequential level. Nonetheless, effect 
sizes should still be interpreted in light of this limitation and the need for further research. 
Relatedly, relatively fewer studies have used the Positive Aspects subscale of the Stigma Scale, 
and as more data becomes available, future research should examine how this construct may 
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differ from the Stigma Resistance subscale of the ISMI. The low internal reliability of both 
measures is also a limitation, and future work should consider ways to improve the measurement 
of the construct of stigma resistance.   
These findings also suggest several important areas for future work. Given the 
relationships observed between stigma resistance and outcomes with significant functional 
implications at the cross-sectional level, more research is needed to understand whether stigma 
resistance precedes improvement in other outcomes (e.g., quality of life or insight) or whether 
other outcomes studied are prerequisites for effectively resisting stigma (e.g., symptom reduction 
or improved insight is necessary before stigma can be effectively addressed and resisted), or if 
the relationships are bidirectional. Second, given the high levels of variability, it seems likely 
that additional moderators, such as duration of illness, may explain unaccounted for between 
study variance. Further work is also needed to examine areas where preliminary work is 
promising but was not frequent enough to examine meta-analytically (e.g., metacognition, 
emotional regulation; Nabors et al., 2014; Raij et al., 2013) in order to better understand whether 
stigma resistance is linked to symptoms and potentially other aspects of recovery. 
Finally, our meta-analytic findings point to stigma resistance as a promising construct 
regarding intervention. Given that resisting stigma was associated with a number of positive 
outcomes (e.g., reduced symptoms and improved functioning), treatment and future research 
should focus on investigating ways to promote stigma resistance or adapt existing interventions 
that target self-stigma in ways that might promote stigma resistance (Mittal et al., 2013; Yanos et 
al., 2012). Given the pervasive impacts of mental illness stigma (Corrigan et al., 2009; Lipsey et 
al., 2001; Lysaker et al., 2007), it seems important to note that stigma resistance was associated 
with improved outcomes for individuals across all diagnostic groups; thus, resisting stigma may 
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be an important cross-diagnostic treatment target. Overall, stigma resistance demonstrated 
notable relationships with a variety of outcomes that are central to recovery and we suggest that 
further work on stigma resistance should guide intervention development in this important 
domain.  
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Table 1   Studies Analyzed  
Study (K=48) N Mean 
Age 
Mean 
Edu 
% 
Female 
% 
White 
% 
Psych
osis 
SR 
α 
Association with SR Measure ES 
Corre
cted 
ES 
Origi
nal 
Boyd Ritsher & 
Phelan (2004)  
126 51 
(10.0) 
-- 6.4 62.1 83.3 0.59 Efficacy/Esteem 
Efficacy/Esteem 
Recovery 
Self/Perceived Stigma 
Self/Perceived Stigma 
Symptoms (Mood) 
RSE 
BUES 
RAS 
PDD 
ISMIS 
CESD 
0.34 
0.37 
0.47 
-0.14 
-0.44 
-0.30 
0.26 
0.28 
0.36 
-0.10 
-0.34 
-0.23 
Brown, et al., 
(2010)  
449 59.6 
(16.4) 
-- 81.0 -- 0.0 0.59 d Self /Perceived Stigma 
Self /Perceived Stigma 
Symptoms (Mood) 
PDD 
ISMIS 
PHQ 
-0.26 
-0.98 
-0.27 
-0.20 
-0.75 
-0.21 
Campellone, 
Caponigro, & 
Kring (2014)  
51 45.9 
(10.6) 
14.4 
(2.5) 
47.0 -- 100.0 0.72 Efficacy/Est 
Self /Perceived Stigma 
Symptoms (Negative) 
Sense of Power 
ISMIS 
CAINS 
0.39 
-0.34 
-0.47 
0.33 
-0.03 
-0.40 
Corrigan, et al., 
(2010)  
85 44.8 
(9.7) 
13.5 
(2.3) 
32.0 34.0 88.0 0.61 Efficacy/Esteem 
Efficacy/Esteem 
Functioning/QL 
Hope 
Self/Perceived Stigma 
Self/Perceived Stigma 
Symptoms (Mood) 
RES 
RSE 
Lehman 
BHS 
ISMIS 
PDD 
CESD-D 
0.56 
0.48 
0.60 
0.32 
-0.49 
-0.20 
-0.33 
0.44 
0.38 
0.47 
-0.25 
-0.38 
-0.16 
-0.26 
Costain, et al., 
(2014)  
25 46.8 
(12.6) 
-- 40.0 -- 100 0.70 Self/Perceived Stigma ISMIS -0.67 -0.55 
Chang, et al., 
(2014)  
347 43.76 
(11.27) 
-- 57.3 0.0 45.1 0.52 Symptoms (Mood) DSSS 0.08 0.06 
Clement, et al., 
(2012)  
117 36.1 
(11.1) 
-- 79.5 87.2 -- 0.62 Self/Perceived Stigma 
 
ISMIS -0.81 -0.64 
Cuhadar & Cam 
(2014) 
47 -- -- 83.0 -- 0.0 0.55 Self/Perceived Stigma 
Functioning/QL 
ISMIS 
BDFS 
-0.16 
0.08 
0.12 
-0.06 
Drapalski, et al., 
(2013) 
100 45.6 
(9.2) 
-- 45.0 -- 42.0 0.58 Efficacy/Est 
Efficacy/Est 
Recovery 
Symptoms (Positive) 
GSE 
RSE 
MHRM 
BSI 
0.39 
0.39 
0.63 
-0.12 
0.30 
0.30 
0.48 
-0.09 
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Symptoms (Mood) 
Symptoms (Mood) 
BSI 
BSI 
-.024 
-0.11 
-0.18 
-0.08 
Evans-Lacko, et 
al., (2012) 
183
5 
43.3 -- -- -- -- 0.65 Efficacy/Est 
Self /Perceived Stigma 
Self /Perceived Stigma 
BUES 
ISMIS 
PDD 
0.56 
-0.53 
-0.21 
0.45 
-0.43 
-0.17 
Farrelly, et al., 
(2014) 
201 
200 
199 
41.8 
(11.1) 
-- 54.5 53.5 47.5 0.58 Self /Perceived Stigma 
Self /Perceived Stigma 
Self /Perceived Stigma 
DISC 
ISMIS 
QUAD 
0.00 
-0.62 
-0.21 
0.00 
-0.47 
-0.16 
Gabbidon, et al., 
(2013) 
117 
91 
54.0 
(12.7) 
-- 52.0 76.0 20.0 0.62  Self /Perceived Stigma 
Self /Perceived Stigma 
ISMIS 
QUAD 
-0.81 
-0.19 
-0.64 
-0.15 
Gibbons, et al., 
(2012) 
33 46.9 
(16.7) 
-- 48.5 66.7 -- 0.42 Self /Perceived Stigma Stigma Q 0.11 0.07 
Griffiths, et al., 
(2014) 
320 
325 
317 
24.6 
(7.1) 
-- 95.1 -- 0.0 0.65 Efficacy/Esteem 
Self/Perceived Stigma 
Symptoms (Mood) 
SES 
ISMIS 
DASS-21 dep. 
0.45 
-0.50 
-0.45 
0.36 
-0.40 
-0.36 
Hasson-Ohayon, 
et al., (2014) 
80 
79 
80 
44.0 
(11.3) 
-- 46.0 -- 100 0.03 Functioning/QL 
Recovery 
Self /Perceived Stigma 
LRI 
RAS 
ISMIS 
0.99 
0.71 
-0.27 
0.19 
0.13 
-0.05 
Hasson-Ohayon, 
et al. (2012) 
60 42.4 
(15.7) 
11.8 
(3.0) 
18.3 -- 78.3 0.18 Insight  
Self /Perceived Stigma 
SAI-E  
ISMIS 
0.73 
-0.52 
0.31 
-0.22 
Kean (2011) 28 45.3 
(10.2) 
-- 39.3 67.9 100.0 0.62 Functioning/QL CASIG 0.52 0.41 
King, et al. 
(2007) 
193 42.9 
(12.4) 
-- 42.5 76.5 52.0 0.64 Efficacy/Esteem 
Self /Perceived Stigma 
RSE 
SS 
0.45 
-0.41 
 
0.36 
-0.33 
Klose (2010) 96 39.7 
(11.5) 
-- 47.9 83.3 17.7 0.58 Efficacy/Esteem 
Self /Perceived Stigma 
GSE 
ISMIS 
0.14 
-0.39 
 
0.11 
-0.30 
Lien, et al., 
(2014) 
160 43.6 
(11.8) 
13.3 
(2.7) 
80.0 -- 64.4 0.75 Efficacy/Esteem 
Efficacy/Esteem 
Hope 
Symptoms (Mood) 
RSES 
GSES 
BHS 
BDI-II 
0.50 
0.39 
0.42 
-0.42 
0.41 
0.32 
0.34 
-0.36 
Lanfredi, et al., 
(2015) 
516 46.6 
(15.3) 
-- 68.2 -- 0.0 0.42 Efficacy/Esteem 
Self/Perceived Stigma 
BUES 
ISMIS 
0.60 
-0.75 
0.39 
-0.31 
Lu & Wang 
(2012) 
92 26.1 
(7.5) 
-- 41.3 0.0 100 0.59 d 
 
Self/Perceived Stigma 
Symptoms (Negative) 
ISMIS 
CSANS 
-0.99 
0.04 
-0.89 
0.03 
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Symptoms (Positive) CSAPS -0.14 
 
-0.11 
Lysaker et al., 
(2007) 
133 46.9 
(9.7) 
12.8 
(1.8) 
8.0 43.5 100.0 0.52 Efficacy/Esteem 
Functioning/QL 
Hope 
Insight 
Self /Perceived Stigma 
Symptoms (Negative) 
Symptoms (Positive) 
MSEI 
QOLS 
BHS 
PANSS 
ISMIS 
PANSS 
PANSS 
0.54 
0.24 
0.64 
0.10 
-0.33 
-0.11 
-0.15 
0.39 
0.17 
0.46 
0.07 
-0.24 
-0.08 
-0.11 
Mashiach-
Eizenberg, et al. 
(2013) 
178 
177 
176 
179 
41.3 
(13.1) 
11.8 
(3.0) 
54.2 -- 100.0 0.59 Efficacy/Esteem 
Functioning/QL 
Hope 
Self/Perceived Stigma 
RSE 
MANSA 
Hope Scale 
ISMIS 
0.12 
0.26 
0.23 
-0.10 
0.09 
0.20 
0.18 
-0.08 
McGuire, et al., 
(2014) 
118 47.7 
(8.9) 
-- 20.0 34.0 100 0.61 Functioning/QL 
Hope 
Self/Perceived Stigma 
Symptoms (Negative) 
Symptoms (Positive) 
Symptoms (Total) 
Recovery 
QOL 
Hope Scale 
ISMIS 
PANSS 
PANSS 
PANSS 
RAS 
0.40 
0.53 
-0.35 
-0.21 
-0.32 
-0.36 
0.51 
0.31 
0.41 
-0.27 
-0.17 
-0.25 
-0.28 
0.40 
Moriarty, et al., 
(2012) 
50 50.1 
(10.6) 
12.73 
(2.2) 
50.0 46.0 100 0.59d Functioning/QL Time Budget 0.31 0.24 
Nabors, et al., 
(2014)   
62 50.9 
(10.6) 
12.7 
(2.2) 
5.0 40.0 100.0 0.50 Efficacy/Esteem 
Self /Perceived Stigma 
Symptoms (Negative) 
Symptoms (Positive) 
Symptoms (Mood) 
RSE 
ISMIS 
PANSS 
PANSS 
PANSS 
0.62 
-0.54 
-0.50 
-0.09 
-0.14 
0.44 
-0.38 
-0.35 
-0.06 
-0.10 
Oscikova, et al. 
(2014) 
76 40.2 
(12.8) 
-- 76.2 -- 0.0 0.64 Self/Perceived Stigma 
Symptoms (Mood) 
Symptoms (Mood) 
Symptoms (Overall) 
ISMIS 
BAI 
BDI 
CGIS 
-0.54 
-0.09 
-0.39 
-0.26 
-.43 
-0.07 
-0.31 
-0.21 
Oscikova, et al. 
(2014) 
369 41.5 
(13.3) 
-- 56.6 -- 10.8 0.58 Self/Perceived Stigma ISMIS -0.39 -0.30 
Park, et al., 
(2013) 
49 49.6 
(7.2) 
11.2 
(2.1) 
28.6 -- 100 0.59 Efficacy/Esteem 
Functioning/QL 
Self/Perceived Stigma 
DAS 
BQOL 
ISMIS 
0.40 
-0.18 
-0.34 
0.31 
-0.14 
-0.26 
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Rusch, et al., 
(2014) 
100 42.0 
(11.3) 
14.7 
(3.2) 
59.0 98.0 27.0 0.60 Efficacy/Esteem 
Efficacy/Esteem 
Self/Perceived Stigma 
Symptoms (Mood) 
BUES 
RSE 
ISMIS 
CES-D 
0.80 
0.77 
-0.72 
-0.57 
0.62 
0.60 
-0.56 
-0.44 
Rusch, et al., 
(2014) 
113 41.0 
(10.0) 
-- 50.9 -- -- 0.60 Efficacy/Esteem 
Functioning/QL 
 
Self/Perceived Stigma 
Self/Perceived Stigma 
Symptoms 
RSE 
WHOQOL-
BREF 
ISMIS 
PDD 
BSI 
0.68 
0.57 
 
-0.59 
-0.39 
-0.43 
0.53 
0.44 
 
-0.46 
-0.30 
-0.33 
Rusch, et al., 
(2014) 
183 -- -- -- -- -- 0.54 Efficacy/Esteem 
Efficacy/Esteem 
Functioning/QL 
 
Functioning/QL 
 
Self/Perceived Stigma 
Symptoms (Overall) 
BUES 
RSE 
WHOQOL-
BREF (soc) 
WHOQOL-
BREF (psych) 
ISMIS 
BPRS 
0.69 
0.60 
0.60 
 
0.37 
 
-0.47 
0.08 
0.51 
0.44 
0.44 
 
0.27 
 
-0.35 
0.06 
Russinova, et al., 
(2014) 
82 -- -- 68.0 70.0 34.0 0.58 Efficacy/Esteem 
Efficacy/Esteem 
Recovery 
Self/Perceived Stigma 
Symptoms (Mood) 
Emp. Scale 
GPSES 
PGRS 
ISMIS 
CES-D 
0.50 
0.42 
0.46 
-0.22 
-0.28 
0.38 
0.32 
0.34 
-0.17 
-0.21 
Sarisoy, et al., 
(2013) 
228 35.6 
(10.3) 
10.4 
(3.8) 
53.0 -- 47.8 0.58 Functioning/QL 
Self/Perceived Stigma 
MRQ  
ISMIS 
0.12 
-0.37 
0.09 
-0.28 
Schrank, et al., 
(2013) 
263 
257 
257 
257 
263 
257 
249 
39.9 
(12.6) 
-- 41.9 -- 100.0 0.71 Hope 
Insight 
Self/Perceived Stigma 
Symptoms (Mood) 
Symptoms (Negative) 
Symptoms (Positive) 
Symptoms (Total) 
IHS 
SAI-E 
ISMIS 
CESD/ADS 
PANSS 
PANSS 
PANSS 
0.66 
0.08 
-0.11 
0.06 
-0.14 
-0.14 
-.020 
0.56 
0.07 
-0.09 
0.05 
-0.12 
-0.03 
-0.17 
Segalovich, et al., 
(2013) 
60 39.9 
(12.9) 
9 (4.3) 20.0 -- 100 0.47 Efficacy/Esteem 
Self/Perceived Stigma 
RSE  
ISMIS 
0.99 
-0.88 
0.60 
-0.77 
Sibitz, et al. 
(2013) 
80 32.1 
(10.5) 
-- 42.5 -- 100 0.59 Self/Perceived Stigma 
Symptoms (Total) 
ISMIS 
PANSS 
-0.62 
-0.09 
-0.50 
-0.08 
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Symptoms (Negative) 
Symptoms (Positive) 
PANSS 
PANSS 
-0.25 
-0.05 
-0.04 
-0.21 
Sibitz, et al. 
(2011) 
157 37.3 
(11.9) 
-- 45.5 100 100 0.73 Efficacy/Esteem 
Efficacy/Esteem 
Functioning/QL 
 
Self/Perceived Stigma 
Self/Perceived Stigma 
Symptoms (Mood) 
RSE 
RES 
WHOQOL-
BREF 
ISMIS 
PDD 
CESD/ADS 
0.60 
0.60 
0.53 
 
-0.33 
-0.30 
-0.54 
0.51 
0.50 
0.45 
 
-0.28 
-0.26 
-0.46 
Silverman (2013) 83 37.6 
(14.7) 
-- 55.0 64.0 7.3 0.64 Self/Perceived Stigma SS -0.64 -0.43 
Sorsdahl, et al., 
(2010) 
142 37.0 
(11.3) 
-- 64.5 -- 58.0 0.59d Efficacy/Esteem 
Self/Perceived Stigma 
Self/Perceived Stigma 
BUES 
ISMIS 
PDD 
0.56 
-0.71 
0.11 
0.43 
-0.54 
0.08 
Staring, Hurrne, 
& Gaag (2013) 
21 40.6  
(--) 
-- 33.3 -- 100 0.25 Efficacy/Esteem 
Hope  
Self/Perceived Stigma 
Symptoms (Mood) 
Symptoms (Negative) 
DAS 
BHS 
ISMIS 
BDI-13 
PANSS 
0.30 
0.59 
-0.23 
-0.40 
-0.34 
0.15 
0.29 
-0.11 
-0.20 
-0.17 
Tang & Wu 
(2012) 
100 46.0 
(10.2) 
-- 19.0 -- 100 0.76 Functioning/QL WHOQOL- 
SF12 
0.33 0.29 
Temilola, et al., 
(2013) 
256 39.5 
(10.6) 
11.8 
(3.0) 
48.0 -- 100 0.50 Functioning/QL 
 
Self/Perceived Stigma 
Symptoms (Positive) 
WHOQOL- 
BREF 
ISMIS 
BPRS 
0.36 
 
0.14 
0.13 
0.25 
 
0.10 
0.09 
Tsai, Lysaker, & 
Vohs (2010) 
77 46.7 
(8.9) 
12.8 
(2.2) 
17.0 29.0 100 0.52 Efficacy/Esteem 
Functioning/QL 
Self/Perceived Stigma 
Symptoms (Mood) 
MSEI 
QLS 
ISMIS 
MAQ 
0.54 
0.21 
-0.54 
-0.33 
0.39 
0.15 
-0.39 
-0.24 
Uhlmann, et al., 
(2014) 
23 35.4 
(11.3) 
14.7 
(3.0) 
39.1 -- 100 0.58 Self/Perceived Stigma ISMIS -0.38 -0.31 
Walston (2012) 100  47.0 
(10.1) 
12.5 
(1.1) 
30.0 51.0 97.0 0.58 Insight 
Insight 
Insight 
Recovery 
Recovery 
BCIS  
BCIS  
IS  
MORS  
MHRM 
0.36 
0.45 
0.26 
0.87 
0.83 
0.27 
0.34 
0.20 
0.66 
0.63 
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Self/Perceived Stigma 
Self/Perceived Stigma 
ISMIS 
ISMIS  
-0.50 
-0.63 
-0.38 
-0.48 
Yanos, et al., 
(2012) 
39 47.1 
(7.9) 
11.5 
(2.9) 
28 20.5 97.0 0.52 Efficacy/Esteem 
Functioning/QL 
Hope 
Symptoms (Negative) 
Symptoms (Positive) 
RSE 
QLS 
BHS 
PANSS 
PANSS 
0.60 
0.08 
0.52 
-0.18 
-0.10 
0.43 
0.06 
0.44 
-0.13 
-0.07 
 
Note. Effect sizes represent the association between stigma resistance and a psychosocial outcome variable. a N represents the sample size 
for the effect size reported., b See Table C4 for scale abbreviation and corresponding full titles., c Original effect sizes, pre-artifact 
correction. d Stigma Resistance alpha unavailable or not obtained from authors. Original alpha of this subscale of .59 from Boyd et al 
(2003) used as a substitute. Scale abbreviations by construct. Efficacy/Esteem: BUES = Boston University Empowerment Scale, DAS = 
Defeatist Performance Beliefs subscale of the Dysfunctional Attitudes Scale, GPSES = Generalized Perceived Self-Efficacy Scale, MSEI 
= Multidimensional Self-Esteem Inventory, RSE = Rosenberg Self Esteem Scale, Sens of Power = Sense of Power Scale. 
Functioning/Quality of Life: BDFS = Bipolar Disorder Functioning Scale, CASIG = Client’s Assessment of   Strengths Interests and 
Goals: Quality of Life subscale, LRI = Life Regard Index, MANSA = Manchester Short Assessment of Quality of Life, MRQ = 
Multidimensional Relationship Questionnaire, PHR = Physical Health Rating, QOLS = Quality of Life Scale, Time Budget = Semi-
structured interview of week-long diary of activities completed (planning, participation, and social contact assessed and rated), 
WHOQOL-BREF/SF12 = World Health Organization Quality of Life-BREF. Insight: BCIS = Beck Cognitive Insight Scale, IS = 
Birchwood’s Insight Scale, PANSS = Positive and Negative Syndrome Scale, SAI-E = Schedule for Assessment of Insight-Expanded 
Version. Hope: Hope Scale = Adult Dispositional Hope Scale, BHS = Beck Hopelessness Scale, HIS = Integrated Hope Scale. Recovery: 
MHRM = Mental Health Recovery Measure, MORS = Milestones of Recovery Scale, PGRS = Personal Growth and Recovery Scale, RAS 
= Recovery Assessment Scale. Self/Perceived Stigma: DISC = Discrimination and Stigma Scale, ISMIS = Internalized Stigma of Mental 
Illness Scale, PDD = Perceived Discrimination Devaluation Scale, QUAD = Questionnaire on Anticipated Discrimination, Stigma Q = 
Stigma Questionnaire, SS = Stigma Scale. Symptoms (Mood): AAS = Annihilation Anxiety Scale, BDI-13 = Dysfunctional Believes 
about Cognitive Abilities, CAINS = Clinical Assessment Interview for Negative Symptoms, CESD/ADS = Center for Epidemiologic 
Studies Depression Scale; Allgemeine Depressionsskala Scale (German version), DASS = Depression Anxiety Stress Scale: An Anxiety 
Measure, DSSS = Depression and Somatic Symptoms Scale, PHQ = Multidimensional Anxiety Questionnaire, MAQ = Patient Health 
Questionnaire. Symptoms (Negative): BPRS = Brief Psychotic Rating Scale, PANSS = Positive and Negative Syndrome Scale. Symptoms 
(Positive): BSI = Brief Symptom Inventory, PANSS = Positive and Negative Syndrome Scale.
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Table 2 
Overall mean effect sizes by outcome grouping (data using Corrected ES’s except for Original ES listed for comparison) 
Corrected ES’s 
 
K N Original  
ES 
Corr  
ES 
SE 95% CI Z Q I2 
Overall outcomes 
 
Self-stigma 
 
Symptoms 
 
Pos symptoms 
 
Neg symptoms 
 
Mood symptoms 
 
Efficacy/Esteem 
 
Functioning/QL 
 
Recovery 
 
Hope 
 
Insight 
48 
 
40 
 
20 
 
8 
 
9 
 
14 
 
25 
 
17 
 
7 
 
8 
 
4 
8187 
 
6861 
 
2684 
 
881 
 
853 
 
2265 
   
5037 
 
1875 
 
833 
 
995 
 
542 
0.32 
 
-0.36 
 
-0.20 
 
-0.11 
 
-0.16 
 
-0.20 
 
 0.42 
 
 0.29 
 
 0.38 
 
 0.40 
 
 0.16 
0.46 
 
-0.57 
 
-0.28 
 
-0.17 
   
-0.23 
 
-0.29 
 
 0.60 
 
 0.51 
 
 0.60 
 
 0.54 
 
 0.38 
0.03 
 
0.06 
 
0.04 
 
0.03 
 
0.06 
 
0.06 
 
0.04 
 
0.12 
 
0.14 
 
0.09 
 
0.17 
[0.40, 0.53] 
 
[-0.69, -0.45] 
 
[-0.35, -0.21] 
 
[-0.24, -0.11] 
 
[-0.35, -0.12] 
 
[-0.40, -0.19] 
 
[0.52, 0.69] 
 
[0.27, 0.75] 
 
[0.32, 0.89] 
 
[0.37, 0.71] 
 
[0.05, 0.72] 
14.19*** 
 
-9.12*** 
 
-7.45*** 
 
-5.02*** 
 
-4.03*** 
 
-5.35*** 
 
 13.84*** 
 
 4.18*** 
 
 4.20*** 
 
 6.29*** 
 
 2.24* 
342.28*** 
 
946.93*** 
 
63.86*** 
 
3.60 
 
19.05* 
 
76.05*** 
 
177.49*** 
 
415.56*** 
 
97.59*** 
 
44.87*** 
 
41.69*** 
 86.27 
 
95.88 
 
70.25 
 
0.00 
 
63.26 
 
89.48 
 
 86.48 
 
 96.15 
 
93.85 
 
 84.40 
 
 92.80 
Note.  K = number of effect sizes used in the calculation of the mean effect size. N = number of participants included in the calculation of 
the mean effect size across studies. ES = weighted mean effect size. SE = standard error. 95% CI = 95% confidence interval for the mean 
effect size. Z = z-test for statistical significance of the mean effect size. A z-score greater than 1.96 indicates statistical significance. Q = 
Test for heterogeneity.  A significant Q indicates greater between-study variability than would be expected by chance.  I2 = I2 index 
indicates the percentage of between-study variability. ***p<.001, *p<.05.  
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Table 3 
Moderator Analyses  
 
Association K (N) B SE 95% CI Z 
SR—Overall outcomes 
Mean Age 
Mean Edu. 
% Female 
% White 
% Psychosis 
 
SR—Self-stigma 
Mean Age 
Mean Edu. 
% Female 
% White 
% Psychosis 
 
SR—Symptoms (total) 
Mean Age 
Mean Edu. 
% Female 
% White 
% Psychosis 
 
SR—Negative Symptoms 
Mean Age 
Mean Edu. 
% Female 
% White 
% Psychosis 
 
SR—Mood Symptoms 
Mean Age 
Mean Edu. 
% Female 
% White 
% Psychosis 
 
 
45 (7,858) 
17 (1,711) 
46 (6,176) 
24 (2,804) 
39 (4,621) 
 
 
38 (7,043) 
14 (1,463) 
39 (5,361) 
18 (2,081) 
32 (3,798) 
 
 
18 (2,402) 
7 (824) 
19 (2,484) 
10 (1,347) 
18 (2,408) 
 
 
9 (853) 
4 (285) 
9 (853) 
4 (352) 
9 (853) 
 
 
13 (2,183) 
5 (584) 
14 (2,265) 
8 (1,039) 
11 (1,423) 
 
 
-0.00 
-0.08 
-0.01 
0.48 
0.02 
 
 
0.02 
0.20 
0.23 
-0.38 
-0.10 
 
 
-0.00 
-0.16 
-0.05 
-0.26 
-0.02 
 
 
-0.01 
-0.11 
0.33 
-0.10 
-1.82 
 
 
0.01 
-0.20 
-0.19 
-0.28 
0.19 
 
 
0.01 
0.06 
0.19 
0.11 
0.10 
 
 
0.01 
0.09 
0.39 
0.17 
0.22 
 
 
0.01 
0.05 
0.17 
0.14 
0.11 
 
 
0.01 
0.10 
0.35 
1.06 
7.14 
 
 
0.01 
0.07 
0.17 
0.16 
0.12 
 
 
[-.02, .01] 
[-.19, .04] 
[-.38, .37] 
[.26, .70] 
[-.21, -.17] 
  
 
[.00, .05] 
[.02, .38] 
[-.55,1.01] 
[-.71, -.05] 
[-.52, .32] 
  
 
[-.02, .02] 
[-.25, -.07] 
[-.39, .30] 
[-.54, .02] 
[-.24, .20] 
  
 
[-.02, -.00] 
[-.31, .08] 
[-.34, 1.01] 
[-2.18, 1.99] 
[-15.82, 12.18] 
 
 
[-.01, .02] 
[-.33, -.06] 
[-.52, .14] 
[-.59, .02] 
[-.05, .43] 
 
 
-0.55 
-1.29 
-0.04 
4.27*** 
-0.22 
 
 
2.00* 
2.18* 
0.58 
-2.26* 
-0.47 
 
 
-0.09 
-3.37*** 
-0.26 
-1.81t 
-0.21 
 
 
-2.44* 
-1.13 
0.96 
-0.09 
-0.26 
 
 
-0.81 
-2.88** 
-1.12 
-1.81* 
1.54 
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Note.  K = number of effect sizes used in the moderation analysis.  N = number of participants 
included in the moderation analysis.  SE = standard error.  95% CI = 95% confidence interval for 
B.  Z = z-test for statistical significance of B.  A z-score greater than the absolute value of 1.96 
indicates statistical significance.  t p<.1,*p < .05, **p<.01, ***p<.001. 1 Insufficient data 
available to perform moderation analysis for education variable.  
 
 
  
Table 3 (Continued) 
Moderator Analyses  
 
Association K (N) B SE 95% CI Z 
SR—Efficacy/Esteem 
Mean Age 
Mean Edu. 
% Female 
% White 
% Psychosis 
 
SR—Functioning/QL 
Mean Age 
Mean Edu. 
% Female 
% White 
% Psychosis 
 
SR—Recovery1 
Mean Age 
% Female 
% White 
% Psychosis 
 
SR—Hope 
Mean Age 
Mean Edu. 
% Female 
% White 
% Psychosis 
 
24 (4,955) 
11 (994) 
24 (3,226) 
13 (1,488) 
22 (2,390) 
 
 
18 (2,402) 
7 (824) 
19 (2,484) 
10 (1,347) 
18 (2,408) 
 
 
6 (751) 
7 (833) 
5 (654) 
7 (833) 
 
 
8 (995) 
5 (593) 
8 (995) 
6 (711) 
8 (995) 
 
-0.00 
-0.06 
-0.13 
0.28 
-0.09 
 
 
-0.03 
0.13 
0.28 
0.30 
0.13 
 
 
0.01 
0.06 
0.10 
0.58 
 
 
0.00 
0.02 
-0.42 
0.70 
0.54 
 
0.01 
0.06 
0.23 
0.18 
0.15 
 
 
0.04 
0.07 
0.74 
0.14 
0.38 
 
 
0.03 
0.70 
0.69 
0.45 
 
 
0.03 
0.11 
0.30 
0.29 
0.37 
 
[-.02, .02] 
[-.18, -.06] 
[-.59, .33] 
[-.08, .63] 
[-.38, .20] 
 
 
[-.11, .05] 
[.00, .27] 
[-1.17, 1.74] 
[.03, .58] 
[-.62, .87] 
 
 
[-.05, .07] 
 [-1.30, 1.43] 
[-1.26, 1.46] 
[-.30, 1.45] 
 
 
[-.05, .05] 
[-.21, .24] 
[-1.02, .17] 
[.13, 1.27] 
[-.19, 1.26] 
 
-0.35 
-0.99 
-0.57 
1.53 
-0.59 
 
 
-0.79 
1.96* 
0.38 
2.16* 
0.33 
 
 
0.29 
0.09 
-0.14 
1.30 
 
 
0.14 
-0.16 
-1.39 
2.40* 
1.46 
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Figure 1 
 
Study Retrieval Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching  
(n = 1871) 
Records identified through 
other sources (n =3) 
Full-text records screened 
 (n =791) 
Records excluded for the 
following reasons (n =686): - Systematic or meta-analytic 
review articles without 
original data (n = 60)  - Did not use ISMI/SS or not 
a mental health sample (n = 
585) - Use ISMI but did not collect 
SR data (n = 3) - Study not available in 
English  (n = 21) - Insufficient information for 
analyses (i.e., published 
abstract and/or no updated 
contact information found)  
(n =17) 
 
 
 
Records with published 
data ready for coding  
(n =10) 
 
Records requiring 
additional information 
(n = 95) 
 Records excluded because 
insufficient information was 
obtained to calculate effect 
sizes after contacting the 
authors (n =38)   
 
Records included in the calculation of 
effect sizes (n =48) 
 
Records included in the 
meta-analysis  
(n =38) 
 
Records excluded because 
sample overlap determined 
after contacting authors  
(n =19)   
 
